| Glaucoma: Trabecular micro-bypass device aids IOP reduction in prospective study
| Stent procedure is additive to pressure-lowering effect of cataract surgery, according to surgeon
| | Ophthalmology Times | Implantation of a trabecular micro-bypass (iStent, Glaukos Corp.) in patients with open-angle glaucoma who are undergoing cataract surgery represents an alternative surgical approach that can provide clinically significant reductions in IOP and use of ocular hypotensive medications. |
| | Canaloplasty may be alternative to trabeculectomy
| Non-penetrating procedure found safe, effective, with similar side effects, no hypotony
| | Ophthalmology Times | | Non-penetrating Schlemm's canaloplasty may be a safe and effective alternative to standard trabeculectomy. A retrospective comparison study found no statistically significant differences in IOP reduction or medication usage at up to 1 year of follow-up. Adjunctive procedures and complications were similar in the two groups of patients, although no long-term hypotony was seen in the canaloplasty group. |
| | | | Glaucoma: Bimatoprost tolerability appears to be enhanced with switching strategy
| Initial therapy with latanoprost associated with reduced risk of hyperemia, study finds
| | Ophthalmology Times | | The efficacy and tolerability of continuing latanoprost 0.005% (Xalatan, Pfizer) after 6 weeks of latanoprost monotherapy versus switching to bimatoprost 0.03% (Lumigan, Allergan) was investigated in an investigator-masked, randomized, parallel-group trial. The results showed good efficacy and tolerability in patients whose therapy was switched to bimatoprost and suggest that bimatoprost may be tolerated better after latanoprost pre-treatment. |
|
| World Sight Day set for Oct. 8
| | Ophthalmology Times E-News
| | Three hundred events in more than 50 countries will mark this year's World Sight Day, Oct. 8. |
| | Aton expands programs for preservative-free timolol
| | Ophthalmology Times E-News | | Aton Pharma has launched new education, distribution, sampling, and reimbursement programs for its preservative-free formulation of timolol maleate (Timoptic in Ocudose), which according to the company is the only preservative-free medication for glaucoma available in the United States. |
| | NicOx and Pfizer sign agreement for PF-03187207
| | Ophthalmology Times E-News | | NicOx has signed an agreement with Pfizer to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open-angle glaucoma and ocular hypertension, according to a prepared statement. |
| | |
| 
Practice Tools
